Share-based payment and ESOP expense

Equity-settled options granted to employees must be expensed over the vesting period at grant-date fair value using an appropriate option-pricing model, which is a significant non-cash expense frequently under-recognized by venture-backed fintechs that view options as 'free' compensation; omitting or understating this expense overstates profitability and understates true compensation cost, which is misleading to investors comparing profitability across peers.

Is the plan equity-settled or cash-settled (phantom shares), and has this classification been made explicitly before applying any measurement model? What service, performance, or market vesting conditions attach to each grant, and how do non-market conditions get trued up for actual forfeitures? Has a defensible grant-date fair value been obtained using an option-pricing model appropriate for an unlisted company (e.g., volatility from comparable peers, equity value anchored to the latest funding round)?

1) Classify each plan as equity-settled or cash-settled (phantom shares), this drives fundamentally different accounting. 2) Identify vesting conditions (service, performance, market) attached to each grant. 3) For equity-settled awards, determine grant-date fair value once (using an option-pricing model suited to an unlisted company) and do not remeasure it subsequently; only the number of awards expected to vest is updated for service/performance conditions. 4) For cash-settled awards, remeasure fair value at every reporting date until settlement, with changes through profit or loss. 5) Recognize the expense over the vesting period on a systematic basis (typically straight-line), with a corresponding credit to equity (equity-settled) or to a liability (cash-settled). 6) True up the cumulative expense for actual forfeitures at each reporting date (service/non-market conditions only; market conditions are not trued up).

Measure equity-settled awards at grant-date fair value using an option-pricing model appropriate for an unlisted company (requiring an estimated volatility, often from comparable listed peers, and an estimated equity value, often anchored to the most recent priced funding round); cash-settled awards are remeasured to fair value at each reporting date until settlement, with cumulative liability reflecting the portion of the vesting period elapsed; do not remeasure equity-settled grant-date fair value for subsequent share price movements.

Disclose: the valuation method and key assumptions (volatility, expected life, risk-free rate, estimated equity value, dividend yield); the number and weighted-average exercise price of options outstanding, granted, forfeited and exercised during the period; the total expense recognized (split equity-settled versus cash-settled); and the carrying amount of any cash-settled liability and its intrinsic value.

• Not recognizing any expense because options have no cash cost to the company
• using an arbitrary or unsupported fair value for an unlisted company'
• s shares instead of a documented valuation methodology
• failing to true-up the expense for actual forfeitures versus original estimates
• remeasuring equity-settled grant-date fair value when it should remain fixed
• misclassifying phantom/cash-settled plans as equity-settled (or vice versa), which changes both measurement and the double entry
• ignoring the impact of a subsequent down-round or repricing on outstanding options (a modification requiring incremental fair value analysis).